Olafiranye Oladipupo, Zizi Ferdinand, Brimah Perry, Jean-Louis Girardin, Makaryus Amgad N, McFarlane Samy, Ogedegbe Gbenga
Brooklyn Health Disparities Center, Department of Medicine, SUNY Downstate Medical Center, Brooklyn, NY 11203, USA.
Int J Hypertens. 2011;2011:653903. doi: 10.4061/2011/653903. Epub 2011 Jul 13.
Evidence suggests that coronary heart disease (CHD) is the most common outcome of hypertension. Hypertension accelerates the development of atherosclerosis, and sustained elevation of blood pressure (BP) can destabilize vascular lesions and precipitate acute coronary events. Hypertension can cause myocardial ischemia in the absence of CHD. These cardiovascular risks attributed to hypertension can be reduced by optimal BP control. Although several antihypertensive agents exist, the choice of agent and the appropriate target BP for patients with CHD remain controversial. In this succinct paper, we examine the evidence and the mechanisms for the linkage between hypertension and CHD and we discuss the treatment options and the goals of therapy that are consistent with the report of the seventh Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) and American Heart Association scientific statement. We anticipate changes in the recommendations of the forthcoming JNC 8.
有证据表明,冠心病(CHD)是高血压最常见的后果。高血压会加速动脉粥样硬化的发展,血压(BP)持续升高会使血管病变不稳定并引发急性冠脉事件。高血压可在无冠心病的情况下导致心肌缺血。通过优化血压控制可降低这些归因于高血压的心血管风险。尽管有多种抗高血压药物,但对于冠心病患者,药物的选择以及合适的血压目标仍存在争议。在这篇简洁的论文中,我们审视了高血压与冠心病之间联系的证据及机制,并讨论了与第七届全国高血压预防、检测、评估和治疗联合委员会(JNC 7)报告以及美国心脏协会科学声明相一致的治疗选择和治疗目标。我们预计即将发布的JNC 8的建议会有所变化。